进行性纤维化间质性肺疾病患者死亡预测因素
基于INPULSIS和INBUILD试验数据,分析进行性纤维化间质性肺疾病患者 demographics/临床变量与52周死亡率的关系。结果显示,FVC相对下降>10%预测值在两组均与死亡风险增加相关,基线DLCO%预测值较高与死亡风险降低相关,支持IPF与其他进行性纤维化ILD病程相似及FVC下降的预测价值。
要点
- FVC相对下降>10%预测值在12个月内与死亡风险增加独立相关。
- 基线DLCO%预测值较高与死亡风险降低相关。
- IPF与其他进行性纤维化ILD的肺损伤病程可能相似。
核心结论
- 数据支持IPF与其他进行性纤维化ILD的肺损伤病程相似,并证实FVC下降是死亡的预测因素。
研究设计与样本
- 汇总INPULSIS试验(IPF患者)和INBUILD试验(其他进行性纤维化ILD患者)数据,分别用Cox比例风险模型分析基线变量和时间变化协变量与52周内死亡时间的关系。
主要发现
- INPULSIS试验52周内68/1061(6.4%)受试者死亡,INBUILD试验33/663(5.0%)受试者死亡。
- INPULSIS试验中,12个月内FVC相对下降>10%预测值(HR 3.77)和年龄(每增加1岁HR 1.03)与死亡风险增加相关,基线FVC%预测值(每增加1单位HR 0.97)和DLCO%预测值(每增加1单位HR 0.77)与风险降低相关。
- INBUILD试验中,12个月内FVC相对下降>10%预测值(HR 2.60)和HRCT上UIP样纤维化模式(HR 2.98)与死亡风险增加相关,基线DLCO%预测值(每增加1单位HR 0.95)与风险降低相关。
临床怎么用
- 在IPF和其他进行性纤维化ILD患者中,监测12个月内FVC相对下降>10%预测值有助于识别死亡高风险个体。
- 基线DLCO%预测值较低可能提示死亡风险增加,需加强随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality. METHODS: The relationships between baseline variables and time-varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model. RESULTS: Over 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1-year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1-unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1-unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia-like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1-unit increase) was associated with lower risk. CONCLUSION: These data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality.
引用
- Brown KK, Inoue Y, Flaherty KR, et al. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology. 2022. PMID: 35224814. doi:10.1111/resp.14231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。